Page 33 - MEMOCiberehd014-ENG

P5. GASTROINTESTINAL AND HEPATIC ONCOLOGY
Coordinator:
Dr. Jordi Bruix
Associate Coordinators: Drs. José Juan García Marín and Antoni Castells
Research Groups:
1- Experimental Hepatology and Drug Vectorization. Antitumor chemotherapy resistance. (Dr . JJ García Marín . U . Salamanca)
2- Molecular Pharmacology and Experimental Therapies. (Dr . M . Pastor . U . Barcelona) 3 .- Gastrointestinal and Pancreatic Oncology (Dr . A Castells . IDIBAPS) 4 .- Colorectal and Gastroesophageal Cancer. Peptic Acid Disease (Dr P . Parrilla . U . Murcia) 5 .- Hepatic Oncology (Dr . J Bruix . IDIBAPS); 6 .- Experimental Hepatology and Gene Therapy (Dr . B Sangro, CUN) 7 .- Gastrointestinal Oncology – Hepatobiliary physiopathology (L . Bujanda, Hospital de Donostia) 8 .- Linked Clinical Group (FJ Padillo, Hospital U . Virgen del Rocío)
The activity of the different lines of activity in this programme in 2014 has resulted in relevant contributions that have increased knowledge about the risk factors and oncogenic mechanisms of both liver and gastrointestinal cancer . The studies have led to diagnostic and therapeutic innovations that have translated into modifications of the clinical management of patients suffering these diseases .
Knowledge about molecular anomalies of hepatocellular carcinoma and cholangiocarcinoma have been expanded in liver cancer, such that in the future, there can be a biological rational base for new treatments . Obviously, better classification of patients must allow a more rational therapeutic assay design .
The most relevant contribution in this field has been describing a genetic anomaly which can determine the hepatocyte or biliary phenotypic pattern of liver cancer .
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer . saha sK, ParachoniaK ca, Ghanta Ks, FitaMant J, ross Kn, naJeM Ms, GuruMurthy s, aKbay ea, sia D, cornella h, MiltiaDous o, walesKy c, DeshPanDe v, zhu aX, hezel aF, yen Ke, straley Ks, travins J, PoPovici-Muller J, Gliser c, Ferrone cr, aPte u, llovet JM, wonG KK, raMaswaMy s, barDeesy n . Nature . 2014 Sep 4;513(7516):110-4 .
Simultaneously, further information has been discovered about the role of the mitochondrial genome in the feedback processes regulating the expression of nuclear genes related to the lack of response of liver cancer to pharmacological therapy .
The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mito- chondrial genome depletion . Gonzalez-sanchez e, Marin JJ, Perez MJ . Molecular Pharmaceutics . 2014; 11(6):1856-68 .
Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors . ariMany-narDi c, errasti-MuruGarren e, Minuesa G, Marti- nez-PicaDo J, Gorboulev v, KoePsell h, Pastor-anGlaDa M . British Journal of Pharmacology (2014) 171(16):3868-80 .
www .ciberehd .org 33